1,3-Dihydro-1-(1,2,3,6-tetrahydro-4-pyridinyl)-2H-benzimidazole-2-one

CAS: 2147-83-3

Ref. 3D-FD149369

Informação sobre produto

• Nome: 1,3-Dihydro-1-(1,2,3,6-tetrahydro-4-pyridinyl)-2H-benzimidazole-2-one
• Sinónimos: 1,3-Dihydro-1-(1,2,3,6-tetrahydro-4-pyridinyl)-2H-benzimidazol-2-one, 1-(1,2,3,6-Tetrahydro-4-pyridyl)-2-benzimidazolinone, 1-(1,2,3,6-Tetrahydropyridin-4-yl)-1,3-dihydrobenzimidazol-2-one, 1-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-benzo[d]imidazol-2(3H)-one, 1-(1,2,3,6-Tetrahydropyridin-4-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one, 1-(1,2,3,6-tetrahydro-4-pyridyl)-1H-benzimidazol-2(3H)-one, 1-(1,2,3,6-tetrahydropyridin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, 2-Benzimidazolinone, 1-(1,2,3,6-tetrahydro-4-pyridyl)-, 2H-Benzimidazol-2-one, 1,3-dihydro-1-(1,2,3,6-tetrahydro-4-pyridinyl)-, 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-benzimidazol-2-one, 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1,2,3,6-tetrahydropyridinium, NSC 88883, R 4748

Descrição

1,3-Dihydro-1-(1,2,3,6-tetrahydro-4-pyridinyl)-2H-benzimidazole-2-one (BZP) is a synthetic chemical compound that has been shown to be effective in the treatment of cancer. It is an agonist of the muscarinic receptor M1 and inhibits phosphatase activity. BZP has been shown to inhibit the growth of carcinoma cells in culture and cause cell death by chloride mediated mechanisms. BZP also binds to the triazole binding site on the protein kinase domain of sorafenib. This binding inhibits sorafenib's ability to inhibit tumor cell proliferation by inhibiting phosphatases and protein synthesis.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 215.25 g/mol
• Fórmula: C₁₂H₁₃N₃O
• Pureza: Min. 95%
• InChI: InChI=1S/C12H13N3O/c16-12-14-10-3-1-2-4-11(10)15(12)9-5-7-13-8-6-9/h1-5,13H,6-8H2,(H,14,16)
• Chave InChI: InChIKey=YFEOSTXFQCDCAR-UHFFFAOYSA-N
• SMILES: O=c1[nH]c2ccccc2n1C1=CCNCC1